Skip to main content
Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine logoLink to Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine
. 2017 Nov;21(11):772–778. doi: 10.4103/ijccm.IJCCM_235_17

Posterior Reversible Leukoencephalopathy Syndrome (PRES) in Intensive Care Unit – Case series

Antara Gokhale 1,, Atheel Kimona 1, Sandeep Kantor 1, S Prakash 1, Yogesh Manhas 1
PMCID: PMC5699006  PMID: 29279639

Abstract

Introduction:

Posterior reversible encephalopathy syndrome (PRES) is characterized by a range of clinico neuro radiological manifestation along with hypertension due to varied etiology. Contrary to its name, a small number of patients have residual neurological deficits. Patients with severe manifestation of PRES may get admitted to the Intensive Care Unit (ICU) due to coma or status epilepticus. Small case series and large multicenter studies have been reported.

Materials and Methods:

We report a single center series of ten cases admitted to ICU over a 5 year period in a tertiary care centre. We retrospectively analyzed patients, admitted to adult ICU with different etiologies, and diagnosed to have PRES. Outcome at discharge and at 90 days after ICU admission was noted.

Result:

The most common etiologies were medications. ICU admissions were mainly for uncontrolled hypertension, seizures, and low level of consciousness. All except one patient were ventilated. Four patients had residual neurological damage.

Conclusion:

Irrespective of the etiology, early control of blood pressure, and removal of precipitating factors is of paramount importance to prevent morbidity and mortality. Awareness about PRES among the intensivist is necessary to ensure early recognition and treatment.

Keywords: ICU, PRES, Neuro-imaging

INTRODUCTION

Posterior reversible encephalopathy syndrome (PRES) is a clinco-radiological diagnosis characterized by acute and varied neurological manifestations along with magnetic resonance image (MRI) findings comprising of hyperintensities on T2-weighted images.

Widely described since 1996, the exact pathophysiology remains unknown.[1] As the name suggests, initially it was described to involve the areas of posterior circulation of the brain; however, subsequently, other areas of the brain have been found to be affected [Figure 1]. About 15%–20% of patients have residual neurological deficits, and the syndrome is not always totally reversible.[2]

Figure 1.

Figure 1

Brain MRI of FLAIR in 25 year old female with eclampsia demonstrating involvement of frontal and occipital lobes along with bilateral basal ganglion

PRES has been described in people with varied clinical etiologies, and the list is ever increasing. Female predominance is seen.[1] Around 35%–40% of patients need mechanical ventilation due to the severity of neurological symptoms and reach the Intensive Care Unit (ICU).[2,3] Epidemiological data for patients admitted in ICU is lacking. We retrospectively analyzed patients admitted to a tertiary care ICU with varied etiologies and diagnosed with PRES over the duration of 5 years.

A high degree of suspicion for early diagnosis and initiation of appropriate treatment is necessary to decrease morbidity and mortality. Treatments include control of blood pressure and remove the causative agent.

PATIENTS AND METHODS

Patients admitted to an adult ICU of a tertiary care unit and diagnosed to have PRES over a 5-year period from 2010 to 2015 were retrospectively analyzed.

Clinical presentation, background medical history, and associated risk factors were reviewed. We documented the neurological status at presentation, namely, the presence of headache, seizures, status epilepticus, and other neurological manifestations. The need for mechanical ventilation, duration of ventilation, and outcome at the time of discharge from ICU was noted. Computerized tomograms (CT) and MRI were reviewed to document the areas involved. Patient's neurological status and residual deficits if any at the time of discharge from the unit and after 90 days period were noted. The possible etiological factors were identified.

RESULTS

Over a 5-year period from 2010 to 2015, we identified ten patients diagnosed with PRES [Table 1]. Out of these patients, four patients had systemic lupus erythematosus (SLE), one newly diagnosed, four had eclampsia of pregnancy, one patient of sickle cell disease with acute chest syndrome, and one with induction chemotherapy for acute lymphoid leukemia [Figures 2 and 3].

Table 1.

Demographic pattern, history, presentation, clinical and radiological features along with outcome of 10 Intensive Care Unit patients with posterior reversible encephalopathy syndrome

graphic file with name IJCCM-21-772-g002.jpg

Figure 2.

Figure 2

Brain magnetic resonance images of fluid attenuation inversion recovery sequence obtained in a 14-year-old male on induction chemotherapy with asparaginase demonstrates moderate bilateral but asymmetrical subcortical and deep white matter vasogenic edema, of parietal and occipital regions

Figure 3.

Figure 3

Brain magnetic resonance images of fluid attenuation inversion recovery sequence obtained in a 14-year-old male on induction chemotherapy with asparaginase demonstrates moderate bilateral but asymmetrical subcortical and deep white matter vasogenic edema, of temporal and parietal regions

Female predominance (male:female-2:8) was seen with age range from 14 to 42 years. Accelerated hypertension was present in nine patients with average blood pressure of 200/100 mmHg. One of the patients had normal blood pressure. All of the patients except one presented with seizures and two patients had status epilepticus. All of the patients complained of headache and three had decreased level of consciousness. Nine patients required mechanical ventilation mainly for airway protection. One patient had repeat clinical and radiological features of PRES after recovery from the first episode within the 90-day period. All patients except one had more than one areas of the brain involved.

Patients were ventilated for 3–15 days and the duration of ventilation was related to underlying etiology and control of the blood pressure. Patients with PRES secondary to eclampsia recovered faster as compared to those with background of chronic hypertension. Two patients with SLE continued to have seizures at the end of 3 months. The MRI in one of the patient showed changes suggestive of vasculitis and the other had new white matter lesions as a part of progression of the disease.

One patient with eclampsia presented with frontal infarction and continued to have left lower leg weakness with a limping gait at the end of 3 months. At the time of ICU discharge, two patients required tracheostomy for weaning from mechanical ventilation secondary to critical illness myoneuropathy and one had cognition impairment.

We lost one patient at the end of 90 days due to complicated Gram-negative septicemia and not related directly to PRES.

All patients with underlying autoimmune disease had chronic hypertension, renal involvement, and were on immunosuppression. Three patients developed PRES after receiving immunosuppression agent that was administered for flare-up of the disease.

As mentioned earlier, one patient developed PRES for the second time 1 month after clinical and radiological recovery from the initial episode, but it is not included as a separate case.

CT scan was the primary imaging done in nine patients and was normal in five. MRI was done in all patients and diagnosis of PRES was established [Table 2].

Table 2.

Observations in patients with PRES

graphic file with name IJCCM-21-772-g005.jpg

DISCUSSION

PRES is a neurotoxic state that presents with varied neurological manifestations such as headache, seizures, encephalopathy, visual disturbance, and less commonly with focal neurological deficits.[2,3] Seizures are seen in 92% of cases[2] with status epilepticus as one of the leading causes of manifestation. This trend was seen in our series as well.

Acute onset of neurological manifestations supported by radiological findings helps to establish the diagnosis of PRES. MRI findings classically include vasogenic edema in subcortical white matter predominantly in the parietal-occipital region [Figure 4]. It may also extend to the frontal, temporal, brainstem, cerebellar, cortical, and subcortical areas [Figures 57].[2,3] The presence of hemorrhage, restricted diffusion, contrast enhancement, and vasoconstriction are all compatible with the diagnosis. MRI shows T2-hyperintense images in the affected areas.[3] About 15%–25% cases can show infracts and hemorrhages.[2,3] In our series, one patient had infarction and two had hemorrhage, i.e., 30% patients had infraction and hemorrhages. The severity is not always related to the number of cortical and subcortical areas involved.[4] More than one areas of the brain were involved in majority of the cases in our series with the involvement of brainstem in three cases. One of the studies has described PRES associated with sepsis to involve the cortical region and that with autoimmune disease the cerebellar region.[4] Although CT scan in acute situations may help to rule out hemorrhage and ischemia, it may not always diagnose PRES; hence, suspected cases should undergo MRI.[5]

Figure 4.

Figure 4

Brain magnetic resonance images of fluid attenuation recovery in a 25-year-old female with eclampsia demonstrates moderate bilateral and symmetrical vasogenic edema in the subcortical white matter maintaining a predominant posterior pattern

Figure 5.

Figure 5

Brain magnetic resonance images of fluid attenuation inversion recovery sequence obtained in a 42-year-old female with systemic lupus erythematosus on immunosuppression, pulsed with steroids, demonstrates marked vasogenic edema involving the brainstem

Figure 7.

Figure 7

Brain magnetic resonance images of fluid attenuation inversion recovery sequence obtained in a 42-year-old female with systemic lupus erythematosus on immunosuppression, pulsed with steroids, demonstrates marked vasogenic edema involving the cerebellar white matter

Figure 6.

Figure 6

Brain magnetic resonance images of fluid attenuation inversion recovery sequence obtained in a 42-year-old female with systemic lupus erythematosus on immunosuppression, pulsed with steroids, demonstrates marked vasogenic edema involving the subcortical, deep, and periventricular white matter of both cerebral hemispheres, maintaining a predominant posterior pattern, along with subcortical involvement and periventricular white matter

The exact pathophysiology is unknown. It is proposed that acute changes in blood pressure lead to loss of autoregulation in cerebral circulation causing hyperperfusion, endothelial damage, and vasogenic edema. The other mechanism is probably due to endothelial dysfunction leading to vasoconstriction, hypoperfusion, and subsequent cerebral ischemia and vasogenic edema.[2]

Hypertension is not found in 25% of the patients, and PRES in these situations is attributed to autoimmune or immune-mediated response.[2,5,6] One of our cases with SLE did not have hypertension.

The etiology is varied and is associated with hypertension, autoimmune diseases, eclampsia and preeclampsia, renal diseases, and cytotoxic and immune-modulating agents.[2] The list is ever increasing as more and more etiologies are identified with neuroimaging diagnosis.[3]

PRES shows female predominance. This was also seen in our series. It may be explained by its association with autoimmune diseases and preeclampsia/eclampsia.

Seizures are the most common presentation along with changes of encephalopathy.[2] High degree of suspicion, prompt control of blood pressure, and withdrawal of the precipitating causes leads to the reversibility of clinical and radiological features. Delay can increase the morbidity and mortality with the development of brain infarcts and hemorrhages. About 15%–20% patients may have neurological consequences; hence, the term “reversible” is questionable.[2,3] At the time of discharge from ICU, four of our patients had residual neurological damage. At 90-day follow-up, two patients continued to have seizures and patients with frontal infarct had lower limb weakness (30%). One patient had a repeat episode of PRES on the background of vasculitis. The MRI images in the same patient showed reversal of PRES but the development of new white matter lesions in the cerebellum and corpus callosum suggesting progression of her underlying disease. It is important to differentiate the neuropsychiatric manifestations that may occur due to cerebral involvement secondary to SLE from those due to PRES. Neuroimaging is helpful. Moreover, PRES-related symptoms are more easily reversible if diagnosed early.[5] The cause of PRES in SLE can be multifactorial, namely, underlying disease activity, hypertension, lupus nephritis, and immunosuppressant medications.[2,6] Two patients had active disease and one was started on induction immunosuppression.

The fourth case had normal blood pressure but developed cardiomyopathy with pulmonary edema along with neurological symptoms. PRES in this situation can be explained by cytotoxic effect of SLE.[2,5]

About 24%–26% of patients can have residual neurological damage. Patients with frontal lobe infarction had residual left lower limb weakness at the end of 3 months. One patient presented to hospital with seizures and low level of consciousness at full-term pregnancy. She had no antenatal visits and underwent emergency cesarean section. Delayed awakening and hypertension prompted neuroimaging. MRI brain showed features of PRES. The patient had impaired cognitive functions despite adequate control of blood pressure. Cytotoxic edema in multiple areas of the brain was still evident on repeat MRI. The delay in diagnosis and control of blood pressure increases the morbidity.

High incidence of PRES has been noted in eclamptics. In a series of 127 patients with eclampsia, 47 patients underwent neuroimaging for persistent hypertension and 46 were found to have features of PRES.[6] Preeclampsia is associated with alteration in blood–brain barrier, which can lead to vasogenic cerebral edema. Microangiopathic changes cause hypertension in eclampsia. PRES is attributed to lack of autoregulation, loss of blood–brain barrier, and endothelial dysfunction all of which are also the proposed etiologies for the development of eclampsia and preeclampsia.[2,6] PRES has been reported in preeclamptics without seizures and without hypertension.[6,7] Three of our patients had seizures postpartum and one before delivery.

Control of blood pressure is most important for reversibility of symptoms. Magnesium sulfate was used in all these patients along with the other antihypertensive medications. The recovery was related directly to control of blood pressure. Patients with postpartum eclampsia recovered faster among the entire series. Since symptoms of PRES may overlap with those of eclampsia and preeclampsia, a high degree of suspicion is required for early diagnosis and control of blood pressure.[8] Delay in diagnosis increases the morbidity as we observed in our case.

Sickling, ischemia, and chronic anemia can contribute to vasogenic edema.[9] Endothelial dysfunction is known to occur in patients with sickle cell disease, and this could further contribute to PRES. MRI helps to distinguish PRES from acute stroke, which is a more common neurological presentation in this group. PRES has been reported in patients with chronic anemia postblood transfusion. Abrupt increase in hemoglobin causes changes in blood viscosity and loss of hypoxemic vasodilation contributing to vasogenic edema.[9,10] Elevated blood pressure and neuroimaging can guide the diagnosis. PRES can occur in sickle cell disease without any of the incriminating factors.[11]

PRES has been associated with multidrug chemotherapy, especially in hematological malignancies. Immunosuppressant drugs such as cyclosporine can cause endothelial damage, which can contribute to vasogenic edema secondary to release of cytokines and inflammatory agents. High-dose steroids, azathioprine, cyclophosphamide, asparaginase, and methotrexate have all been individually associated with PRES.[12,13,14] Some of our patients were on one or more of these medications when diagnosed with PRES. Since primary disease control is equally important, expert help is required to modulate the medications so as to control both, the disease and symptoms of PRES.

Since patients in ICU may be ventilated and critical with a variety of co-existing problems, awareness and suspicion of PRES is important.

CONCLUSION

With the increased use of neuroimaging, especially MRI, more and more cases of PRES are being diagnosed. Patients in ICU may be ventilated and critical with a variety of etiologies, and intensivists should be aware about the possibility of PRES. A high index of suspicion in patients with hypertension along with neurological manifestations should prompt a radio imaging to confirm PRES. It is well established that early diagnosis along with control of blood pressure and removal of the precipitating factors is important to decrease the morbidity and improve outcome.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  • 1.Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. Areversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500. doi: 10.1056/NEJM199602223340803. [DOI] [PubMed] [Google Scholar]
  • 2.Legriel S, Pico F, Azoulay E. Understanding posterior reversible encephalopathy syndrome. In: Vincent JL, editor. Annual Update in Intensive Care and Emergency Medicine. Berlin, Heidelberg: Springer; 2011. pp. 631–53. [Google Scholar]
  • 3.Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: Fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29:1036–42. doi: 10.3174/ajnr.A0928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: Clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14:914–25. doi: 10.1016/S1474-4422(15)00111-8. [DOI] [PubMed] [Google Scholar]
  • 5.Liu B, Zhang X, Zhang FC, Yao Y, Zhou RZ, Xin MM, et al. Posterior reversible encephalopathy syndrome could be an underestimated variant of “reversible neurological deficits” in Systemic Lupus Erythematosus. BMC Neurol. 2012;12:152. doi: 10.1186/1471-2377-12-152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brewer J, Owens MY, Wallace K, Reeves AA, Morris R, Khan M, et al. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. Am J Obstet Gynecol. 2013;208:468.e1–6. doi: 10.1016/j.ajog.2013.02.015. [DOI] [PubMed] [Google Scholar]
  • 7.Edvardsson B. Hypertensive encephalopathy and cerebral infarction. Springerplus. 2014;3:741. doi: 10.1186/2193-1801-3-741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Poma S, Delmonte MP, Gigliuto C, Imberti R, Delmonte M, Arossa A, et al. Management of posterior reversible syndrome in preeclamptic women. Case Rep Obstet Gynecol. 2014;2014:928079. doi: 10.1155/2014/928079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Solh Z, Taccone MS, Marin S, Athale U, Breakey VR. Neurological PRESentations in sickle cell patients are not always stroke: A Review of posterior reversible encephalopathy syndrome in sickle cell disease. Pediatr Blood Cancer. 2016;63:983–9. doi: 10.1002/pbc.25932. [DOI] [PubMed] [Google Scholar]
  • 10.Aiyer R, Klein D, El-Sherif Y. Rare case of posterior reversible leukoencephalopathy syndrome secondary to acute chest syndrome. Case Rep Radiol. 2016;2016:4346953. doi: 10.1155/2016/4346953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Landais A, Lemonne N, Etienne-Julan M. Uncommon posterior reversible encephalopathy syndrome in a sickle-cell patient. J Clin Neurol. 2015;11:287–8. doi: 10.3988/jcn.2015.11.3.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Foocharoen C, Tiamkao S, Srinakarin J, Chamadol N, Sawanyawisuth K. Reversible posterior leukoencephalopathy caused by azathioprine in systemic lupus erythematosus. J Med Assoc Thai. 2006;89:1029–32. [PubMed] [Google Scholar]
  • 13.Morrow SA, Rana R, Lee D, Paul T, Mahon JL. Posterior reversible encephalopathy syndrome due to high dose corticosteroids for an MS relapse. Case Rep Neurol Med. 2015;2015:325657. doi: 10.1155/2015/325657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Aradillas E, Arora R, Gasperino J. Methotrexate-induced posterior reversible encephalopathy syndrome. J Clin Pharm Ther. 2011;36:529–36. doi: 10.1111/j.1365-2710.2010.01207.x. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine are provided here courtesy of Indian Society of Critical Care Medicine

RESOURCES